Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome
Relapsed/Refractory Chronic Lymphocytic Leukemia · Small Lymphocytic Lymphoma · Richter's Syndrome · Treatment-naïve High Risk Chronic Lymphocytic Leukemia
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 1/2
- Patients
- 194 (final count)
- Started
- Nov 25, 2020
- Main results expected
- Dec 2027
- Fully finished
- Feb 2028
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Dose Escalation Phase and Safety Run-in (R/R CLL arm): Number of Participants with Dose Limiting Toxicities (DLTs)
Measured over: During the first cycle for low dose cohorts (Cycle length = 28 days) and for high dose cohorts (Cycle length = 35 days)
Dose Escalation Phase and Safety Run-in: Number of Participants with Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Measured over: Up to 5 years
Dose Escalation Phase: Number of Participants with Cytokine Release Syndrome (CRS), Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) and Clinical Tumor Lysis Syndrome (CTLS)
Measured over: Up to 5 years
Expansion Phase: Overall Response Rate (ORR)
Measured over: Up to 5 years
Changes Tremor has spotted
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT04623541 · record last updated 2026-11-04 · checked 2026-11-09 15:47 UTC